Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
DOMAIN Therapeutics

DOMAIN Therapeutics

A biopharmaceutical company discovering and developing small molecules that target G protein-coupled receptors

DOMAIN Therapeutics is a company that is committed to improving patients’ life by delivering innovative cancer immunotherapies and treatments for neurologic disorders and rare diseases.

The company aims to make an impactful difference for patients who suffer from cancer by discovering treatments that address GPCR -mediated immunosuppression.

The company develops a robust pipeline in immune-oncology and progresses its advanced programs towards the clinic, using its expertise, innovative approach and proprietary platform.

The company has also built a pipeline of GPCR-based programs in neurology and rare diseases over the past decade. Domain is developing by establishing early partnerships on its neurology and rare disease assets..

Timeline

May 10, 2022
DOMAIN Therapeutics raises a $42,000,000 series A round from CTI Life Sciences Fund, Omnes Capital, Panacea Venture, Seventure Partners, Turenne Capital, Viva BioInnovator and adMare BioInnovations.
October 1, 2006
DOMAIN Therapeutics raises a $8,200,000 series C round from Andera Partners, Auriga Partners, Bpifrance, Groupe Siparex, IDInvest Partners and Sofinnova Partners.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 8, 2020
BioSpace
CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma, have come together to establish a new Montreal -based drug discovery and development company, Find Therapeutics, de

References

Golden logo
By using this site, you agree to our Terms & Conditions.